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As articulated in its FP2020 Commitment, Ghana aims to increase the modern contraceptive prevalence rate 
(mCPR) among currently married or in-union women from 22 percent to 29 percent and among unmarried 
adolescents from 32 percent to 35 percent by 2020, with a focus on improving access in peri-urban and rural 
areas and at all service delivery levels, building the capacity of health providers, and improving the contraceptive 
method mix. Injectables are the most commonly used family planning (FP) method among married women in 
Ghana, with 8 percent of married women using the method, and a commonly used method among sexually 
active unmarried women, with 7 to 8 percent using the method.  
Most injectable users use depot medroxyprogesterone acetate (DMPA) administered intramuscularly (DMPA-
IM), though recently, a subcutaneous version of DMPA (DMPA-SC) has become more widely available. DMPA-
SC—also known by its brand name Sayana® Press (a registered trademark of Pfizer Inc.)—has a shorter needle 
and slightly lower dosage than DMPA-IM, but maintains a three-month injection frequency and has similar 
safety features and potential side effects as DMPA-IM. DMPA-SC is suitable for community-based distribution 
as well as self-injection by clients, due to it being small, light, and easy to use, and requiring minimal training. 
The possible benefits of self-injection include increased access, privacy, and autonomy for its users. 
The Evidence Project, led by the Population Council with support from the United States Agency for 
International Development (USAID)/Ghana, collaborated with the Ghana Health Service (GHS) to conduct a 
feasibility and acceptability study introducing DMPA-SC to health providers and FP clients in Ghana, results of 
which would inform the scale-up of DMPA-SC, including self-injection, in the public and private sectors of the 
country. The objectives of the study were to:  
 Assess the feasibility and acceptability of DMPA-SC service provision by FP providers and clients in 
Ghana. 
 Assess the feasibility and acceptability of client self-injection by FP providers in Ghana. 
 Assess the feasibility and acceptability of self-injection by FP clients in Ghana. 
The study was conducted in rural, peri-urban, and urban areas of the Ashanti and Volta regions of Ghana. All 
FP-related providers at selected health facilities were eligible to participate in the study. Providers received a 
three-day training on DMPA-SC counseling and subcutaneous administration, training clients to self-inject, and 
observing and supervising clients’ use of DMPA-SC. Immediately before and after the training, providers 
completed pre- and post-training assessments to gauge improvements in knowledge.  
Clients who sought FP services and chose to use DMPA-SC after receiving counseling on the method were 
eligible to participate in the study. After choosing DMPA-SC, clients were given the option to be trained on self-
injection and, if deemed competent by the provider, to self-inject under supervision of the provider and to take 
two doses of DMPA-SC home for future self-injection. Clients who agreed to participate in the study were 
interviewed at the facility after their first injection and over the phone or in person following their scheduled 
second injection (3-month interview) and third injection (6-month interview). 
A total of 568 clients who chose DMPA-SC agreed to participate in the study. Sixty percent were 18 to 29 years 
old, 73 percent were married or in-union, and 71 percent had attained junior secondary level of schooling or 
higher. Of 150 trained providers who participated in the study, 65 percent were community health nurses and 
88 percent had at least one year of experience in their professional capacity. Key findings of the study included: 
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Approximately four out of ten (41%) DMPA-SC clients in this study had never used any (modern or traditional) 
method of FP. 
• Forty-eight percent of clients had recently used intramuscular injectables (DMPA-IM). 
• Seventy-one percent of clients who were new FP users continued to use DMPA-SC at 6 months, 
compared with 64% of clients who had ever used any method of FP.  
• While just over one-third of DMPA-SC clients chose to self-inject their first time using DMPA-SC 
(35%), nearly two-thirds (65%) chose to self-inject at 3 months and 6 months.  
• At 6 months, self-injection was more common among women 18 to 29 years (76%) compared to women 
30 years and above (68%), never-married women (81%) compared to ever married/in-union women 
(69%), first-time FP users (81%) compared to previous modern FP users (65%), and women living in 
rural areas (87%) compared to urban residents (64%).  
• At 6 months, two out of three clients (67%) continued using DMPA-SC, a total of 9 months of 
protection. 
• Continuation of DMPA-SC was more common among never-married (74%) compared to currently 
married (65%) and previously married (59%) women. Women from the Volta region were more likely 
to continue (75%) compared to women in the Ashanti region (58%).  
 
• 44 percent of DMPA-SC clients chose to self-inject at home. 
• At 6 months, clients who took DMPA-SC doses home reported high satisfaction (98%) and comfort 
(100%) with home self-injection.  
• Home self-injectors also reported benefits such as not having to travel to the facility (71%), not having 
to wait at the facility (47%), privacy (42%), and not having to see a provider (37%).  
• Nearly all home self-injectors knew how to correctly store (96%) and dispose of (98%) the used 
Uniject™ device, found it easy to store (94%) and dispose of (96%), and reinjected on time (85%)  
(within an 11-to-17-week window after the previous injection).  
At the end of the training, over 90 percent of providers correctly answered questions on five key characteristics 
of DMPA-SC: 
• 98 percent knew that Uniject™ is the injection device for DMPA-SC, an increase from 34 percent 
before the training. 
• 93 percent knew that DMPA-SC is administered subcutaneously, up from 29 percent before the training. 
• 99 percent knew DMPA-SC is administered every 3 months, an increase from 52 percent before the 
training. 
• 100 percent knew that DMPA-SC must be stored at room temperature, compared to 55 percent before 
the training. 
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• 100 percent could name at least one location on the body where DMPA-SC can be injected, compared 
to 61 percent before the training. 
At the end of the training, almost all providers reported that they were very well prepared to offer DMPA-SC 
services to clients: 
• 94 percent of providers felt very well prepared to counsel clients on DMPA-SC. 
• 93 percent felt very well prepared to administer DMPA-SC. 
• 93 percent felt very well prepared to train clients to self-inject. 
• 98 percent felt very well prepared to observe and supervise clients during self-injection.  
The findings of this study suggest that providers can be trained to counsel their clients on DMPA-SC, administer 
DMPA-SC, and train and supervise their willing clients to self-inject. Additionally, both providers and clients 
found self-injection of DMPA-SC to be feasible and acceptable. The following recommendations aim to guide 
the Ghana Health Service as it scales DMPA-SC up nationally: 
: 
• Develop an implementation strategy for staggered rollout across the nation, in public and private health 
facilities.  
• Utilize a cascade training approach similar to the study, whereby national and regional resources persons 
are trained to become Master Trainers, who then train providers on-site. This will efficiently allow for 
the number of providers who are trained to be maximized across the country. 
• Engage pharmacies and over-the-counter medical sellers in commodity resupply, enabling them to sell 
DMPA-SC to women who have received self-injection training at the facility and amplifying the role of 
the private sector in increasing uptake of DMPA-SC in Ghana.  
: 
• Develop national guidelines and standards governing home self-injection of DMPA-SC, to be included 
in the next edition of the National Reproductive Health Service Policy and Standards. 
• Develop national guidelines and standards for disposal and waste management of used devices for 
facilities and home self-injection clients. 
: 
• Raise awareness by integrating DMPA-SC in relevant health promotion and social marketing activities 
in the community and at health facilities. 
: 
• Enforce the use of the standard Adverse Reaction Reporting Form in public and private facilities as well 
as pharmacies and over-the counter medical seller shops as part of pharmacovigilance. 
• Add DMPA-SC and its modalities as a method option on FP registries and daily logs, to enable public 
and private facilities to contribute to national monitoring and reporting of DMPA-SC use. 
• Include global DMPA-SC indicators in monitoring and evaluation tools to enable comparisons of trends 
with other countries.  
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• Develop an action plan for monitoring disposal and waste management for facilities and home self-
injection clients. While 95 percent of clients stored DMPA-SC correctly and 98 percent disposed of it 
correctly, this study did not follow women for long enough to know if they would also return their 
disposal container to the facility at the time of resupply. 
• Conduct regular assessments of client experiences with DMPA-SC, including reinjection, storage, and 
disposal practices, as well as reasons for discontinuation of DMPA-SC, and a comparison of these 
reasons to those for discontinuation of DMPA-IM. As self-injection is a new mode of administration 
in Ghana, monitoring its use from the clients’ perspective will be critical in understanding successes and 
challenges of home injection for learning across the region.  
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Ghana’s Family Planning 2020 (FP2020) commitments include increasing the modern contraceptive prevalence 
rate (mCPR) among currently married or in-union women to 29 percent and among unmarried adolescents to 
35 percent by 2020, with a focus on improving access to voluntary family planning (FP) in peri-urban and rural 
areas. Specifically, the Government of Ghana has made a commitment to increase the number of women using 
modern contraception from 1.46 million as of 2015 to 1.93 million in 2020 via increased access and availability 
of services at all service delivery levels, building capacity of health providers, improving the contraceptive 
method mix, and increasing demand for FP services (FP2020 2017). 
The most recent nationally representative data, the Ghana Demographic and Health Survey conducted in 2014 
and the Ghana Maternal Health Survey conducted in 2017, indicate that the mCPR among married women is 
between 22 percent (GSS et al. 2015) and 25 percent (GSS et al. 2018), and among sexually active unmarried 
women is between 31 percent (GSS et al. 2017) and 32 percent (GSS et al. 2018), with a total fertility rate between 
3.9 and 4.2 births per woman (GSS et al. 2018; GSS et al. 2015). A sizeable unmet need for FP remains, with 
approximately 30 percent of married women and 42 percent of unmarried women in Ghana wanting either no 
more children or to postpone childbearing for at least the next two years, but not using any method of 
contraception (GSS et al. 2015). 
In 1988, 0.3 percent of married women in Ghana reported using injectables; this proportion steadily increased 
to 8 percent in 2014 (GSS et al. 2015), making injectables the most commonly used method among married 
women. Among married modern contraceptive users, nearly one-third (32 percent) reported using an injectable, 
and among unmarried modern contraceptive users, 22 percent use an injectable (GSS et al. 2017). With a failure 
rate of less than one percent for perfect use and less than 4 percent for typical use (Trussell 2011; Polis et al. 
2017), injectable contraceptives are highly effective, reversible, and convenient to use, and can ensure privacy 
and secrecy (Adetunji 2011).  
The most commonly used injectable contraceptive method by women around the world, including women in 
Ghana, is the progestin-only depot medroxyprogesterone acetate (DMPA). DMPA can be administered either 
as an intramuscular (IM) injection or as a subcutaneous (SC) injection. There are several similarities between 
DMPA-SC and DMPA-IM, including three-month injection frequency, safety, and side effects (Figure 1, adapted 
from PATH). Compared to DMPA-IM, DMPA-SC has a shorter needle and slightly lower dosage, and the 
subcutaneous injection is administered using the all-in-one Uniject™ device (Figures 1 & 2). DMPA-SC is small, 
light, and easy-to-use, and requires minimal training (PATH 2017a; PATH 2017b). DMPA-SC is often referred 
to by its brand name of Sayana® Press1, a registered trademark of Pfizer, Inc. 
The Uniject™ injection system has been described as especially suitable for community-based distribution and 
for women to administer themselves through self-injection (PATH 2017a; PATH 2017b). As such, DMPA-SC 
and the possibility of self-injection have become promising pathways for increasing access to a safe and effective 
contraceptive option in low-resource settings (Keith et al. 2014). In addition, self-injection of DMPA-SC is a 
method of self-care for women, and thus has the potential to increase the privacy and autonomy of users to 
decide whether, when, and how many children to have (Murray et al. 2017). As of December 2018, DMPA-SC 
                                                     
1 In this report, DMPA-SC is used for general references to the injectable contraceptive method, while Sayana® Press is 
used for specific references to the product used in the study and mentioned in data collection tools. At the time the study 
was conducted, the product was widely referred to as Sayana® Press in Ghana and elsewhere. Of note is that providers 
were trained on DMPA-SC, but for consistency with the product packaging, providers counseled and trained clients using 
the name Sayana® Press.  
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was available in about 20 FP2020 countries and has been approved by regulatory bodies in more than 40 
countries around the world (PATH 2018). In Ghana, it is registered as Sayana® Press by Pfizer, Inc. and is 
approved for use by the Food and Drug Authority. 
Between 2012 and 2015, pilot studies on the feasibility and acceptability of DMPA-SC were undertaken in 
Senegal and Uganda (Burke et al. 2014). Introductions of DMPA-SC began in Burkina Faso, Niger, Senegal, and 
Uganda in 2014 through a variety of channels, including clinic and community-based health providers. In a span 
of two years (2014-2016), providers administered more than 490,300 doses of DMPA-SC to women and reached 
135,000 women who were first-time users of modern FP (PATH 2017a).  
The pilot studies revealed a demand for self-injection. In Senegal and Uganda, close to 90 percent of clients 
participating in studies demonstrated competency to self-inject three months after being trained by a provider, 
and a large proportion of women in these studies expressed a desire to continue with self-injection (Cover et al. 
2017a; Cover et al. 2017b). Subsequent studies on continuation conducted in Malawi, Senegal, Uganda, and the 
United States all showed that over a 12-month period, women who self-injected DMPA-SC at home continued 
using this injectable contraceptive method longer than their counterparts who received injections from clinic or 
community-based providers (Burke et al. 2018; Cover et al. 2018; Cover et al. 2019; Kohn et al. 2018). 
 
FIGURE 1. SIMILARITIES AND DIFFERENCES BETWEEN DMPA-IM AND DMPA-SC  
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In 2016, the Ghana Health Service (GHS) reached out to its partners, namely the United States Agency for 
International Development (USAID), the United Nations Population Fund (UNFPA), Population Services 
International (PSI), and Population Council, to undertake a feasibility and acceptability study regarding DMPA-
SC self-injection, and, by extension, the introduction of the contraceptive method to the country (see Appendix 
1 for study partner roles). At the time, acceptability studies had been conducted in Senegal and Uganda which 
examined clients’ willingness to self-inject (Burke et al. 2014). Introduction of DMPA-SC through service-
delivery channels had commenced in Burkina Faso, Niger, Senegal, and Uganda.  
Although three self-injection studies were ongoing in 2016 in Malawi, Senegal, and Uganda, results were not 
available at the time the present study was conceived. There was, therefore, a palpable need to broaden the 
evidence base on the feasibility and acceptability of DMPA-SC self-injection in Ghana and other sub-Saharan 
countries. Moreover, Ghana aimed to contribute to the growing body of evidence by conducting a study in a 
context where DMPA-SC and self-injection would be introduced simultaneously. 
The current research study was funded by USAID/Ghana and led by the Population Council through the 
Evidence Project. It was carried out in two regions and across eight public health facilities (four in the Ashanti 
region and four in the Volta region), over an 8-month period. 
This report details the study, including the objectives, intervention components, methodology, and results. It 
also includes a discussion section that interprets the findings and a final section that highlights the utilization of 
research findings to inform DMPA-SC scale-up.  
 
FIGURE 2. A VISUAL OF THE UN IJECT™ SYSTEM 
 
Photo credit: PATH, copyright 2018.  
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The aim of the study was to introduce DMPA-SC (using Sayana® Press) to health providers and FP clients in 
Ghana. The study had three primary objectives: 
 Assess the feasibility and acceptability of DMPA-SC service provision by FP providers and clients in 
Ghana. 
 Assess the feasibility and acceptability of client self-injection by FP providers in Ghana. 
 Assess the feasibility and acceptability of self-injection by FP clients in Ghana. 
Results of the study have informed the scale-up of DMPA-SC, including self-injection, in the public and private 
sectors of the country.  
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The study was implemented with providers and clients of DMPA-SC in the Ashanti and Volta regions of Ghana. 
The study included a quantitative self-assessment among providers trained in providing DMPA-SC and in 
training clients to self-inject DMPA-SC. The assessment was implemented before the training and right after the 
training concluded. For DMPA-SC clients, a prospective cohort study design was implemented. Clients who 
selected DMPA-SC were interviewed at the facility after receiving their first injection and then again over the 
phone after the scheduled second and third injections, which could have occurred at the facility or at home. In 
some instances, clients’ second and third interviews were conducted in person when a phone interview was not 
feasible either due to connectivity issues and/or client expressing a strong preference for an in-person interview. 
The study was implemented in selected public health facilities in the Ashanti and Volta regions. The Ashanti 
region is currently the most populous region of the country with approximately 5 million people. The total 
fertility rate (TFR) in the Ashanti region is 4.4 births per woman and modern contraceptive prevalence rate 
(mCPR) is 21 percent. The 2014 Demographic and Health Survey (DHS) showed that approximately 6 percent 
of married women are using an injectable (GSS et al. 2015). The Volta region is home to approximately 3 million 
people. The TFR is 3.6 births per woman and the mCPR of 30 percent is the highest in the nation (GSS et al. 
2015). Furthermore, 14 percent of married women in the Volta region are using an injectable (GSS et al. 2015). 
Both Ashanti and Volta regions are predominantly rural. 
In each region, four facilities—two rural, one peri-urban, and one urban—were selected across four districts 
(Table 1). The facilities were eligible for the study based on their rural/urban location, monthly caseload of 
injectable users, and tracking of service statistics using rsLog.2 At the national level, the GHS Family Health 
Division (FHD) informed the Regional Directors of the Ashanti and Volta Regional Health Directorates about 
the study. The Regional Director and Deputy Director in Charge of Public Health (DDPH) then contacted 
District Directors and Facility In-Charges of eligible facilities to inquire about their willingness to participate as 
a study site.  
 
TABLE 1. STUDY SITES, BY LOCATION 
Ashanti Region Volta Region Location 
Maternal and Child Health Hospital  Council Hall Family Health Unit  Urban 
Abuakwa Health Centre  Juapong Health Centre  Peri-Urban 
Piase CHPS  Tsito Health Centre  Rural 
Fumso Health Centre  Helekpe Health Centre  Rural 
                                                     
2 rsLog is a health management information system tool developed by the GHS with technical assistance from Population 
Council that allows for: monitoring of individual health worker performance by cadre; disaggregation of data by facility, 
district, regional, and national levels; and generation of monthly electronic reports. 
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Providers 
Providers at selected facilities who had at least six months of experience providing FP services were eligible for 
participation in the study. Eligible providers included community nurses, enrolled nurses, midwives, and others 
providing FP services. Facility In-Charges were informed about the study and asked to provide a list of eligible 
FP-related providers (i.e., reproductive and child health unit, antenatal unit, and outpatient unit) reporting to the 
facility. These providers were informed about the study during a site visit in October 2017 and all FP-related 
providers agreed to be recruited into the study in November 2017.  
Clients  
Clients eligible for the study included women aged 18-49 years who were seeking FP services at the selected 
health facilities. Women who were planning on becoming pregnant in the next three months and those less than 
6 weeks postpartum and breastfeeding were excluded from the study, as were those who were unable to provide 
a phone number as a contact or unwilling to be reached by phone. 
Trained providers counseled clients seeking FP services on a range of contraceptive methods. Providers were 
trained to counsel clients on DMPA-SC and self-injection mode of administration and to provide an opportunity 
to train clients on-site to self-inject. After a client who had chosen DMPA-SC received an injection (either 
through self-administration or provider administration), providers informed them about the research study. 
Clients who agreed to learn more about the study were introduced to a research team member stationed at the 
facility. The research team member implemented the informed consent process. Written informed consent was 
obtained from all clients. Clients who were not able to sign their name attested that the consent form had been 
read and explained to them by a member of the research staff by marking the space with an “x.”  
Clients were enrolled from December 2017 to January 2018 in the Ashanti and Volta regions until the desired 
sample size was reached. The desired sample size was calculated based on an estimated 25 percent of DMPA-
SC users choosing to self-inject after six months (or at the third injection).  
The sample size was calculated based on the following formula: 
 
Where, n = minimum sample size 
Z= 1.96 (standard) 
p = 0.25 (estimated proportion of DMPA-SC users who opt for self-injection at t0+6months) 
d = 0.05 (5% absolute precision or margin of error) 
The minimum sample size derived from this formula is 289. Given the longitudinal nature of the research, the 
design effects, non-random sampling of women seeking FP services, and loss to follow-up were considered. The 
calculated sample sizes were multiplied by a standard factor of 1.5 (design effect) and divided by 0.80 (20% loss 
to follow up). This results in a total minimum sample size of 540 DMPA-SC users across both regions. The 
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samples were divided equally between both regions with approximately 60 percent from the urban facilities 
(Table 2).  
 
TABLE 2. EXPECTED CLIENT SAMPLE SIZE, BY REGION  
 Ashanti Volta 
Urban/Peri-urban 
Health Facility 1 81 81 
Health Facility 2 81 81 
Rural 
Health Facility or CHPS Compound 1  54 54 
Health Facility or CHPS Compound 2 54 54 
Total 270 270 
Thirty-two data collectors (16 per region) were recruited in October 2017 and trained in November 2017 to 
conduct client interviews. In rural facilities where the expected client enrollment was 54, three data collectors 
were recruited to conduct 18 interviews each. Likewise, five data collectors were recruited for each urban and 
peri-urban facility where the expected client enrollment was 81. To equalize the number of interviews conducted 
by each data collector, the enrollment was increased to 90 in the urban and peri-urban facilities. 
In both regions, data collectors were trained over a 3-day period. The training included an overview of the study 
and its goals; FP methods available and use trends in Ghana; the principles of research, including ethical conduct, 
privacy, and confidentiality; the informed consent process and consent forms; the role of the data collector in 
administering informed consent forms and ensuring confidentiality and privacy; review of the different study 
instruments, interview questions, and their respective purposes; and data collection timelines and data 
management.  
Both trainings included a combination of PowerPoint presentations, quizzes, role-plays, and practice using the 
tablets and troubleshooting data collection issues. The study instruments were developed in English and 
translated orally into Ewe (the predominant language in the Volta region) and Twi (the predominant language 
in the Ashanti region) during the trainings. In the event of disagreements, data collectors deliberated and came 
to a consensus on terminology to use. Client interviews were conducted in the participant’s preferred language 
(i.e., English, Ewe, or Twi), while the provider self-administered questionnaires were in English.  
Providers 
Providers completed self-administered paper-based questionnaires before and after the training in November 
2017. The purpose of these questionnaires was to evaluate changes in knowledge related to FP counseling and 
contraceptive methods in general, and particularly DMPA-SC counseling and administration, as a result of the 
training received. The pre-training questionnaire gathered information on providers’ sociodemographic 
characteristics (age, educational level, gender) as well as professional data (length of service provision, cadre, 
average number of clients served per month). In addition, the questionnaire asked providers about FP counseling 
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and provision experience as well as clinical practice. Providers completed the same questionnaire at pre-training 
and post-training, although the latter included some additional questions about the training experience and self-
reported preparedness to administer DMPA-SC and teach self-injection to clients.  
Clients 
Data collection with clients began in the first week of December 2017 in Ashanti Region and second week of 
December 2017 in Volta Region. Three rounds of client interviews were conducted. Data collection about 
clients’ first injection experiences ended in the last week of January 2018 in both regions. Data collection about 
clients’ second and third injection experiences spanned March to April 2018 and June to July 2018, respectively.  
The first interview was conducted immediately after the client first received DMPA-SC at the health facility, and 
the second and third interviews were conducted at three-month intervals, at 3 months and 6 months, to 
correspond with clients’ scheduled reinjection dates. The first interview was conducted in-person at the facility, 
after the first injection. The majority of these interviews were conducted in a private space at the health facility, 
although some clients preferred to be interviewed in another private space outside of the facility. Interviews at 
3 months and 6 months were originally intended to be conducted over the phone after the scheduled reinjection 
window for each client. However, some clients encountered connectivity issues, while others perceived that they 
would face social harms for spending long periods of time on the phone, preferring instead that the interviews 
be conducted face to face at the facility or at home, which the research team accommodated. Home self-injectors 
identified a private space for the interview, usually in their homes.  
The questionnaire about clients’ first injection experience included information on sociodemographic 
characteristics, previous FP use, awareness of Sayana® Press, quality of care during the FP visit, Sayana® Press 
counseling messages received, experiences with Sayana® Press injection training and administration, intention 
to continue using Sayana® Press, home self-injection pack received (for those administering at home), and 
reporting of serious adverse reactions. Additional questions in the 3-month and 6-month interviews focused on 
the most recent injection experience, experience of side effects, and experiences with home self-injection for 
those who chose to administer DMPA-SC at home, including ease of home self-injection, storage and disposal 
of the device, and reinjection dates.  
Clients who declined to participate in the study after the first injection, withdrew from the study by 3 months or 
6 months, or discontinued using DMPA-SC by 3 months or 6 months were asked to participate in a separate 
interview with questions about their reasons for declining, withdrawing, or discontinuing the method. 
Health service statistics 
DMPA-SC service delivery data were collected throughout the study using rsLog, a health management 
information system (HMIS) tool developed by the GHS with technical assistance from Population Council. 
Unlike the typical national HMIS used in the majority of West African countries into which aggregated data is 
entered, rsLog allows for monitoring of individual health worker performance, by cadre; disaggregation of data 
by facility, district, regional, and national levels; and generation of monthly electronic reports. Using rsLog, the 
number of doses of DMPA-SC administered daily by cadre of health worker was captured. Data from rsLog 
was collected for 10 months to help gauge continuation of DMPA-SC after the study period. Data from rsLog 
was used for monitoring purposes and as part of the assessment of the feasibility of introducing DMPA-SC in 
health facilities in Ghana. These data were not analyzed for this report. 
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Provider responses from the pre- and post-training questionnaires were double entered manually into Census 
and Survey Processing System (CSPro) by two different data analysts to reconcile any inconsistencies.  
Interviews with clients were conducted using an electronic tablet pre-loaded with time-appropriate 
questionnaires. Data collectors entered client responses into CSPro software installed on tablets. The data were 
sent via a secure server to data supervisors who checked them for completeness and accuracy. Raw provider and 
client data were accessible only to the research management team, namely the data supervisors, principal 
investigator, program manager, research specialist, and the technical director. Only de-identified and aggregated 
data were shared with stakeholders.  
For both the provider and client data, descriptive statistics and bivariate analyses were conducted using Stata 15 
software. Specifically, chi-square tests and t-tests were used to determine significant differences.  
The research protocol, including the informed consent forms and data collection tools, was approved by the 
Population Council Institutional Review Board in November 2016 and the GHS Ethical Review Committee in 
April 2017.  
Structured and written informed consent forms were administered in-person to providers before the trainings 
began and to willing FP clients after taking their first DMPA-SC injection. All who agreed to participate in the 
study were asked to sign the forms and were given a copy for their records. Clients who were not able to sign 
their name attested that the consent form had been read and explained to them by a member of the research 
staff by marking the space with an “x.” In subsequent rounds, clients provided verbal consent to data collectors 
to conduct the interviews. The informed consent forms detailed the (a) study purpose, objectives, and duration; 
(b) methodology; (c) interview procedures; (d) measures to protect their privacy, confidentiality, and anonymity 
of information provided; (e) risks and benefits; (f) right to withdraw from the study or to refuse answering 
questions at any point of the study; (g) compensation (clients were compensated with a bar of soap for their 
time); (h) contact information of ethical review boards; and (i) who to contact for additional information or if 
there was a problem. Master Trainers read the informed consent form to providers and explained its contents 
and data collectors did the same with clients before seeking their written consent if they agreed to be part of the 
study. All who declined to participate in the study were informed that they would be asked a few questions to 
help understand their reasons, to which they were also given the choice to decline responding.  
Each respondent was assigned a unique identification (ID) number prior to completing the first interview or 
responding to the “Decline, Withdraw, or Discontinue” (DWD) interview. The unique ID was prefilled for 
subsequent interviews. For providers, the unique ID was assigned when entering the data. As such, the 
questionnaires with their names were kept in a locked cabinet at the Population Council office in Accra, Ghana 
and will remain locked until 2022 as per Population Council research data and confidentiality procedures. 
Informed consent forms were kept in a separate locked cabinet in the same office.   
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Technical Advisory Group  
The Population Council convened a Technical Advisory Group (TAG) in August 2016 to discuss and agree on 
the self-injection study objectives. Comprising stakeholders from the public, private, and non-governmental 
sectors (see Table 3 for list of participant organizations), the TAG remained active to provide guidance on study 
regions, study design and methods, study intervention, product registration approach, and expected roles of 
study partners. The diverse composition of the TAG was deliberate and based on the expected private sector 
role in the event of a scale-up of DMPA-SC. The TAG held six face-to-face meetings between August 2016 and 
November 2018 during which data collection updates were presented, findings discussed, and input and 
feedback received. Outside of face-to-face meetings, the TAG remained engaged throughout the study period 
via regular email updates. 
 
Sayana® Press was approved as a contraceptive product by the Food and Drugs Authority (FDA) in November 
2016, paving the way for discussions with the Regional Health Directorates of the Ashanti and Volta Regions. 
In both regions, meetings were held in January 2017 with the Regional Health Director, Deputy Director for 
Public Health (DDPH), and the Regional Public Health Nurse to discuss the study, intervention, and proposed 
study sites. Upon agreement, the Regional Health Directors delegated their DDPH to further inform respective 
District Directors and Facility In-charges. 
Inception meetings were organized in the two regions: one in the Ashanti region in February 2017 and another 
in the Volta region in March 2017. In both regions, meetings were attended by the GHS leadership at the 
regional, district, and facility levels. The meetings were also attended by the leadership of the GHS Family Health 
Division (national) and by representatives of USAID/Ghana’s Health, Population, and Nutrition Office. The 
meetings included a presentation on the study rationale, objectives, intervention, and other proposed activities, 
followed by discussions on topics such as storage, waste, disposal, stock availability, and pricing of DMPA-SC.  
All In-Charges of the facilities communicated their willingness to be selected as a study site to the Regional 
Health Directorate. In October 2017, the study team visited the eight study facilities to engage directly with the 
In-Charges as well as the providers to discuss the study, introduction of DMPA-SC in Ghana using Sayana® 
Press, a recap of the inception meeting, and the provider trainings. This was also an opportunity for providers 
to ask questions and clarify that their training would be separate from their consent to participate in the research 
study.  
The study involved a three-step training cascade: 
1. Training of Master Trainers 
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The Family Health Division (FHD) of the GHS identified eight of its Regional Resource Trainers (four per 
region) to be trained by a Master Trainer from PATH Uganda, a country where DMPA-SC and self-injection 
feasibility and acceptability studies had been conducted. The 4-day training took place in mid-October 2017. 
The training focused on DMPA-related topics outlined in Box 1 using PowerPoint slides derived from a 
standardized training guide developed by PATH. At the request of the FHD, a one-page information sheet for 
clients on adverse and severe adverse reactions as well as actions to take was developed and reviewed in the 
training. This form was separate from the Adverse Reaction Reporting Form developed by the FDA for 
pharmacovigilance and used by GHS. The training also included role-plays for providers to practice how to 
administer DMPA-SC and train clients on self-injection.  
Before the training, the Regional Resource Trainers completed a pre-training evaluation. They completed a post-
training evaluation on the last day of the training to ascertain gains in DMPA-SC knowledge from the training. 
The PATH Master Trainer certified the Regional Resource Trainers as Ghana Master Trainers in DMPA-SC 
and self-injection.  
2. Training of health providers 
The eight Ghana Master Trainers trained a total of 
150 health providers (71 in Ashanti Region and 79 in 
Volta Region) across the eight selected study 
facilities. Each week in November 2017, 3-day 
trainings were conducted simultaneously in each 
region (except for 2-day trainings in two rural 
facilities, due to small staff size). In each facility, 
training was conducted among staff from various 
FP-related departments (e.g., antenatal, reproductive 
and child health, nutrition) and of different cadres 
(i.e., community nurses, enrolled nurses, midwives, 
and others) (Table 6). 
The Ghana Master Trainers used the same PATH 
resources and training guide to train the health 
providers. The topics and lessons were delivered via 
PowerPoint presentations, and hardcopies of the job 
aids were made available. The tools used in the 
training included:  
1. Provider injection checklist: This checklist was used by 
the Master Trainers to observe providers practicing 
administering DMPA-SC injections on clients.  
2. Observation checklist for Sayana® Press self-injection 
practice: This observation checklist developed by PATH was used by the Master Trainers to observe providers 
during their role play of training clients to practice DMPA-SC self-injection and by the providers to observe 
clients during their actual practice of self-injection. 
3. Reinjection calendar (2017-2018): This calendar spanning two years aided clients in remembering when to return 
to the facility for reinjection or when to reinject at home. All home self-injection clients were given the calendar.  
1. General overview of family planning 
2. Overview of DMPA 
a. What is DMPA-SC? 
b. What is Uniject™? 
c. DMPA-IM and DMPA-SC: similarities and 
differences 
d. Mode of action and route of administration 
3. Screening women for DMPA 
4. Counseling women for DMPA 
5. HIV risk and hormonal contraceptives including 
DMPA 
6. Safe storage and handling sharps 
7. Provider-administered DMPA-SC injection 
8. Counseling women on DMPA-SC self-injection 
9. Training women to self-inject 
10. Training clients to safely store DMPA-SC 
11. Training clients to safely dispose of used Uniject™ 
devices 
12. Training clients to calculate reinjection dates 
13. Side effects management 
14. Client follow up options 
16 | RESEARCH REPORT 
4. Client self-injection instruction sheet: This one-page sheet (front and back) with pictorial instructions was designed 
as a visual aid for clients to remember the steps required for safe self-injection. All home self-injection clients 
were given this sheet. 
5. Adverse Reaction Reporting Form: This form was developed by the FDA and is used by GHS as part of 
pharmacovigilance. Providers were (re)trained to use this form to report adverse reactions to the GHS. 
6. Adverse reaction information sheet for clients: This one-page sheet was developed for the purposes of the study to 
help clients recognize the signs of severe adverse reactions and where to seek immediate medical attention. 
7. DMPA-SC job aids for providers: These job aids developed by PATH were given to each provider to take back 
to their facilities and use when providing DMPA-SC services.  
Additionally, providers completed a self-administered questionnaire to determine their knowledge before the 
training and a similar questionnaire after the training to gauge any changes in knowledge on FP in general and 
DMPA-SC in particular. These questionnaires were developed for the purposes of the study. 
In Volta region, providers were also trained on inputting data into rsLog, the health information system. No 
trainings were needed in Ashanti region as providers in the study facilities were already using the rsLog system. 
3. Training of family planning clients 
Trained providers counseled FP clients at the facility on all 
available contraceptive methods, including DMPA-SC and 
on its two modes of administration (i.e., provider-
administered or client self-administered). Among clients 
who desired to use DMPA-SC, their eligibility to receive the 
method was based on the World Health Organization’s 
Medical Eligibility Criteria for Contraceptive Use (WHO 
2015).  
Providers offered clients an option to be trained by the 
provider to self-inject or to receive the injection by the 
provider. If a client chose to self-inject, she was given the 
opportunity to practice self-injection up to five times on a 
condom filled with salt, to mimic the fat under skin, under 
the supervision of the provider. The provider deemed the 
client competent to self-inject when a client successfully 
executed the five critical self-injection steps (out of 11 total 
steps) (see Box 2, critical steps in bold), using the 
observational checklist (tool #2 listed in training description 
above) and his or her own clinical judgement. Providers also 
trained self-injection clients on calculating future injection 
dates, safe home storage, and safe disposal into a puncture-
proof container.  
Clients who chose provider-administered injection and did 
not practice self-injection or despite a self-injection practice, 
clients who failed to be competent in self-injection were 
informed about their follow-up visit, and the date for the 
Step 1: Washes hands. 
Step 2: Selects an appropriate injection site and 
cleans it if needed. 
Step 3: Opens the Sayana® Press pouch by tearing 
from the notch.  
Step 4: Mixes the liquid by shaking the device 
vigorously for about 30 seconds.  
Step 5: Pushes the needle cap and port together to 
activate the device.  
Step 6: Removes the needle cap. 
Step 7: Pinches the “skin” at the injection site to form 
a “tent”.  
Step 8: Inserts the needle completely so that the port 
is in full contact with the skin. 
Step 9: Presses the reservoir slowly to inject for about 
5 to 7 seconds. 
Step 10: Removes the device from the injection site 
while still pinching the skin.  
Step 11: Immediately places the used device in a 
sharps disposal container without replacing the 
needle cap.  
Bold indicates critical steps. 
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visit was indicated on their FP card. Clients who were trained to self-inject and deemed competent were given 
up to two DMPA-SC doses for home self-injection, along with the 2017-2018 reinjection calendar with dates 
for the next injections circled, the self-injection instruction sheet, and the puncture-proof disposable container 
for disposing of the used devices. Self-injection clients were also asked to return the container with the used 
devices to the facility at any point during the study for final disposal, but especially after the third injection when 
they returned to receive additional doses.  
The UNFPA procured 6,000 doses of DMPA-SC (Sayana® Press), which were sent to the Central Medical 
Stores. Given that no requisition forms existed for the DMPA-SC, the commodities were transported to the 
regional health directorates by the Evidence Project with approval from GHS-FHD and received by the 
respective Regional Public Health Nurses.  
The number of commodities per facility was determined by assuming a scenario in which all clients chose self-
injection. Calculations took into consideration the three doses needed for each client, regardless of mode of 
administration, four doses needed for self-injection practice, and one dose to cover an additional three months 
after the study. Each client was allocated a total of eight doses. An additional 30 percent of doses were added 
for clients who selected DMPA-SC but declined participation in the study. A reserve of doses was stocked at 
the regional medical stores for procurement during and after the study. Each rural facility received 562 doses of 
DMPA-SC while each peri-urban and urban facility received 936 doses. 
 
TABLE 3. LIST OF ORGANIZATIONS INVOLVED IN TECHNICAL AD VISORY GROUP 
Organizations Sector represented 
United States Agency for International Development (USAID) Donor 
Ghana Health Service (GHS) Public 
The Evidence Project, through Population Council INGO 
United Nations Population Fund (UNFPA) Donor 
Population Services International (PSI) INGO 
Strengthening Health Outcomes through the Private Sector 
(SHOPS) 
INGO 
Pfizer, Inc. Private 
Planned Parenthood Association of Ghana (PPAG) NGO 
Health Keepers Network (HKN) NGO 
DKT International  NGO – Social Enterprise 
In both regions, Master Trainers conducted supportive supervision visits to each study facility three months 
post-training (February 2018). At each facility, using the observation checklist for self-injection practice, Master 
Trainers observed each provider simulating the steps for training clients to self-inject. Where necessary, the 
Master Trainers aided providers to improve technique and reinforce knowledge. Additionally, Master Trainers 
completed a supportive supervision form to assess the readiness of the facility and of providers to successfully 
continue providing DMPA-SC services.  
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Immediately following the data collectors’ training, a WhatsApp group was created for each region. The groups 
included the respective data collectors, the research team, and the data management team. This platform was 
used to exchange information from the research management team and for data collectors to initiate any 
discussions related to tips or any challenges encountered during fieldwork. The platform also served as a tool 
for continued supervision by the data management team.  
Representatives from the TAG, specifically USAID/Ghana, GHS Family Health Division, and Population 
Council, visited the Volta region in May 2018. Alongside two Master Trainers, the TAG representatives met 
with the Regional Health Directorate followed by visits to Helekpe Health Centre and Council Hall Family 
Health Unit. During these visits, they interacted with the providers and In-Charges. TAG members took the 
opportunity to ask questions about providers’ experiences with DMPA-SC, training clients on self-injection, and 
waste and disposal, as well as any implementation challenges encountered. Providers also took the opportunity 
to ask questions about GHS’ plans for expansion and scale-up after the study ended.  
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Across both regions, 568 clients who chose DMPA-SC agreed to participate in the study. Table 4 presents the 
sociodemographic characteristics of clients enrolled in the study at the time of their first injection. More than 
half of respondents were between 18 and 29 years old (60%), and the majority were married or in-union (73%). 
Half had attained junior secondary school/junior high school (JSS/JHS) level (50%) and 22 percent had attained 
senior secondary school/senior high school (SSS/SHS) level or higher. More clients were enrolled in urban areas 
(60%), though by region, the distribution was almost equal. Enrollment by facility was a function of the estimated 
sample size. Almost 60 percent of clients had previous experience using a modern or traditional FP method and 
over three-quarters (76%) of respondents reported that their partner supported their use of FP. For most clients 
(72%), the travel time to the facility was less than 30 minutes.  
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TABLE 4. PERCENT DISTRIBUTION OF STUDY PARTICIPANTS BY 
SOCIODEMOGRAPHIC CHARACTERISTICS AT FIRST INJECTION (N=568)  
  N Percent 
Age group*   
   18-24 185 32.6 
   25-29 156 27.5 
   30-34 107 18.8 
   35-39 62 10.9 
   40-44 33 5.8 
   45+ 24 4.2 
Marital status   
   Never married 155 27.3 
   Ever married/in-union 413 72.7 
Education   
   No education 55 9.7 
   Primary 107 18.8 
   JSS/JHS 282 49.7 
   SSS/SHS or higher 124 21.8 
Region   
   Ashanti 278 48.9 
   Volta 290 51.1 
Residence   
   Rural 226 39.8 
   Urban 342 60.2 
Facility   
   Maternal & Child Health Hospital 90 15.9 
   Abuakwa Health Centre 79 13.9 
   Piase CHPS 54 9.5 
   Fumso Health Centre 55 9.7 
   Council Hall Family Health Unit 84 14.8 
   Helekpe Health Centre 55 9.7 
   Tsito Health Centre 62 10.9 
   Juapong Health Centre 89 15.7 
Contraceptive experience   
   Previous FP user 334 58.8 
   New FP user 234 41.2 
Partner supports FP use   
   No/don't know 137 24.1 
   Yes 431 75.9 
Travel time to reach facility   
   Less than 30 minutes 410 72.2 
   30 minutes to 60 minutes 130 22.9 
   More than 60 minutes 28 4.9 
Total  568 100.0 
*Percentages may not add to 100 percent due to missing values 
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Notably, 41 percent of respondents had never used any method of FP (Figure 3), while 59 percent had previously 
used either a modern or traditional method (Table 4). Figure 3 shows the FP method most recently used by 
clients before choosing DMPA-SC. Nearly half of respondents (48 percent) reported having used an injectable 
most recently, and 6 percent reported having used an implant. The remaining 5 percent reported having used 
oral contraceptive pills, withdrawal, male condoms, emergency contraception, abstinence, or the Standard Days 
Method®.  
 
FIGURE 3. MOST RECENTLY USED FAMILY PLANNING METHOD AMONG DMPA-SC 
CLIENTS (N=568)  
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During their FP counseling sessions, clients who selected DMPA-SC were offered an opportunity to be trained 
in self-injection and, if deemed competent by the provider, could self-inject. Otherwise, the provider could inject 
the DMPA-SC. Figure 4 shows the administration mode selected by clients at each injection among respondents 
who were successfully interviewed at each follow-up interview. For the first injection, about one-third of clients 
(35%) were successfully trained in and completed self-injection at the facility. At 3 months, 65 percent of clients 
surveyed selected self-injection (21% on site at the facility and 44% at home), while 29 percent selected provider-
administered injection and 7 percent discontinued using DMPA-SC. By the end of the study, at 6 months, most 
clients (65 percent) selected self-injection (23% at the facility and 42% at home), 24 percent selected provider-
administration, and 11 percent discontinued DMPA-SC.  
 
FIGURE 4 .  CLIENTS’ SELECTED MODE OF INJECTION ADMINISTRATION, BY 
INTERVIEW 
 
Figures 5-9 detail the distribution of clients’ selected administration mode of DMPA-SC at 6 months, by select 
sociodemographic characteristics (additional information on mode of injection administration at each interview 
by background characteristics is available in Appendix 2). Chi-squared tests of significance were conducted to 
assess differences between provider-administered and self-injection. Those who self-injected at 3 months or 6 
months, whether at home or at the facility, were grouped together as self-injectors for these chi-squared tests.  
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Figure 5 presents clients’ mode of injection administration by age. There was a statistically significant difference 
between age groups in choosing self-injection (p-value <0.05). At 6 months, about three-quarters of 18 to 24-
year-olds (78%), 25 to 29-year-olds (74%), and 30 to 34-year-olds (78%) were self-injection clients, compared to 
65 percent of 35 to 39-year-olds and 51 percent of those 40 years and older. A greater proportion (49 percent) 
of those 40 years and older chose provider-administration of DMPA-SC. Self-injectors comprised those who 
self-injected at home and at the facility. Those 25 to 29 years old were most likely to have self-injected at home 
at 6 months (56%), followed by 30 to 34 years old (50%) and 18 to 24 years old (45%). Those 35 to 39 years old 
as well as 40 years and older were less likely to self-inject at home (36% of each age group). On-site self-injection 
was most likely among those 18-24 (32 percent), followed by 35-39 (29%), and 30-34 (28%) years.  
 
FIGURE 5 .  CLIENTS’ MODE OF INJECTION ADMINISTRATION AT 6 MONTHS, BY AGE 
(N=378)  
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At 6 months, there was a significant difference between marital status groups (p-value <0.05) in self-injection of 
DMPA-SC (Figure 6). Eighty one percent of never married clients and 69 percent of ever married/in-union 
clients self-administered DMPA-SC, with 55 percent of never married clients and 44 percent of those ever 
married/in-union being home self-injection clients. Similar proportions of ever-married/in-union women and 
never married women self-injected on-site, at 25 percent and 26 percent, respectively. A greater percentage of 
those who were ever married/in-union chose provider-administered injections (31%) compared to those who 
were never married (20%).  
 
FIGURE 6 .  CLIENTS’ MODE OF INJECTION ADMINISTRATION AT 6 MONTHS, BY 
MARITAL STATUS (N=378)  
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Statistical difference in self-injection by marital status: p-value ≤0.05 
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There was no statistically significant difference in choosing self-injection among educational groups at 6 months, 
with 64 percent of those with no education, 79 percent of those with primary, 70 percent of those with JSS/JHS, 
and 78 percent of those with SSS/SHS self-injecting at 6 months (Figure 7). However, there appears to be an 
increase in specifically home self-injection by education level, as 35 percent of those with no education, 40 
percent of clients with primary, 48 percent with JSS/JHS, and 56 percent of those with SSS/SHS chose to self-
inject at home at 6 months. More than one-third of those with primary education chose to self-inject on-site, at 
39 percent, followed by 29 percent of those with no education. Similar proportions of those with junior and 
senior or higher levels of education self-injected on site, at 22 percent each. 
 
FIGURE 7 .  CLIENTS’ MODE OF INJECTION ADMINISTRATION AT 6 MONTHS, BY 
EDUCATION (N=378)  
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Respondents who lived in rural locations were significantly more likely to self-inject at 6 months than those in 
urban locations, with 87 percent of those living in rural locations choosing to self-inject compared to 64 percent 
of those in urban locations (Figure 8). For home self-injection specifically, 80 percent of respondents living in 
rural locations chose to self-inject at home, compared to 27 percent of those living in urban areas, whereas 37 
percent of women in urban areas chose on-site self-injection compared to 7 percent of rural women. 
 
FIGURE 8 .  CLIENTS’ MODE OF INJECTION ADMINISTRATION AT 6-MONTHS, BY 
RESIDENCE (N=378)  
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Figure 9 demonstrates that those who were first-time FP users were significantly more likely to self-inject, at 81 
percent, than those who had used a modern or traditional method of FP prior to using DMPA-SC, at 65 percent. 
A greater proportion (53%) of first-time FP users also self-injected at home compared to previous FP users 
(43%), while similar proportions self-injected on-site (28% of first-time FP users compared to 23% of previous 
FP users).  
 
FIGURE 9 .  CLIENTS’ MODE OF INJECTION ADMINISTRATION AT 6 MONTHS, BY 
HISTORY OF FAMILY PLANNING USE (N=378)  
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Figure 10 presents the proportion of clients who continued to use DMPA-SC through the end of the study, that 
is, a total of 9 months of protection. At 3 months, 76 percent of clients continued using DMPA-SC, 6 percent 
had discontinued using DMPA-SC, and 18 percent had withdrawn from the study or were lost to follow-up. By 
6 months, 67 percent of clients were still using DMPA-SC, while 8 percent had discontinued3 using DMPA-SC, 
and 25 percent had withdrawn from the study or were lost to follow-up. 
 
FIGURE 10. CONTINUATION AND DISCONTINUATION OF DMPA-SC AND STUDY 
WITHDRAWAL/LOSS TO FOLLOW-UP, BY INTERVIEW (N=568)  
  
Table 5 presents differences in continuation of DMPA-SC at 6 months by client characteristics. Continuation 
of DMPA-SC includes provider-administered, on-site self-injection, and home self-injection clients. 
Discontinuation includes those who stopped using DMPA-SC, those who were lost to follow-up, and those 
that withdrew from the study. There were no significant differences in continuation of DMPA-SC by age, 
education, urban/rural residence, and travel time to reach the facility. However, continuation was statistically 
different by marital status, with those who were never-married (74%) being more likely to continue using than 
those who were currently married (65%), and those who were formerly married being the least likely to 
continue (59%). There were also statistically significant differences in continuation by region, with respondents 
in Volta region being more likely to continue (75%) than those in Ashanti region (57%). Those who had 
previous experience using FP were less likely to continue using DMPA-SC (64%) compared with new FP users 
(71%) although, the relationship was not statistically significant (p-value <0.1).  
                                                     
3 Data were not collected on whether discontinuers of DMPA-SC switched to another FP method. 
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TABLE 5. CONTINUATION OF DMPA-SC AT 6 MONTHS BY CLIENT BACKGROUND 
CHARACTERISTICS (N=568) 
†p-value <0.05 indicating significant differences 
 
  
  Discontinued (%) Continued (%) p-value 
Age group    
   18-24 (n=185) 33.0 67.0 0.481 
   25-29 (n=156) 37.2 62.8  
   30-34 (n=107) 32.7 67.3  
   35-39 (n=62) 24.2 75.8  
   40+ (n=57) 35.1 64.9  
Marital status†   0.050 
   Never married (n=155) 26.5 73.5  
   Currently married/in-union (n=323) 34.7 65.3  
   Formerly married/in-union (n=90) 41.1 58.9  
Education   0.291 
   No education (n=55) 43.6 56.4  
   Primary (n=107) 34.6 65.4  
   JSS/JHS (n=282)  33.0 67.0  
   SSS/SHS or higher (n=124) 29.0 71.0  
Region†   <0.001
† 
   Ashanti (n=278) 42.4 57.6  
   Volta (n=290) 24.8 75.2  
Residence   0.245 
   Rural (n=226) 36.3 63.7  
   Urban (n=342) 31.6 68.6  
Contraceptive experience   0.063 
   Previous FP user (n=334) 36.5 63.5  
   New FP user (n=234) 29.1 70.9  
Travel time to reach facility   0.208 
   Less than 30 minutes (n=410) 32.2 67.8  
   30 minutes to 1 hour (n=130) 39.2 60.8  
   More than 1 hour (n=28) 25.0 75.0  
Total (n=568) 33.5 66.5  
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Clients who discontinued using DMPA-SC but were not lost to follow-up reported a variety of reasons for 
discontinuing the method (Figure 11). Experiencing side effects was the most common reason, as reported by 
44 percent of clients who discontinued using DMPA-SC. Approximately 23 percent reported inconvenience as 
a reason for discontinuation, while 16 percent discontinued to switch to a different method of FP. Other reasons 
for discontinuing included that the client was traveling, the possibility of experiencing adverse or serious effects, 
the fear of getting pregnant, wanting to become pregnant, difficulty storing the devices, and an unsupervised 
injection environment. Nine percent did not list a reason for discontinuing.  
 
FIGURE 11 .  CLIENTS’  REPORTED REASONS FOR DISCONTINUING DMPA-SC AT 3 
MONTHS OR 6 MONTHS (N=80)  
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Clients who had selected self-injection and were deemed competent to self-inject were given up to two DMPA-
SC doses to take home. Those who self-injected at home at 3 months (n=203) and at 6 months (n=178) were 
asked about different aspects of acceptability of home self-injection (Figure 12). Clients reported high levels of 
satisfaction (100% at 3 months and 98% at 6 months) and high levels of comfort with their home self-injection 
experience (100% at 3 months and 6 months). Ninety-five percent at 3 months and 97 percent at 6 months 
reported that they would recommend DMPA-SC home self-injection to a friend. Almost all intended to continue 
home self-injection in the future (98% at 3 months and 97% at 6 months). 
  
FIGURE 12. ASPECTS OF ACCEPTABILITY AMONG HOME SELF-INJECTION CLIENTS 
AT 3 MONTHS AND 6 MONTHS 
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Home self-injection clients reported on the benefits of self-injecting at home (Figure 13). The benefit most often 
cited was not having to travel to the facility (75% at 3 months and 71% at 6 months). Other benefits commonly 
reported by home self-injection clients included not having to pay for travel to the facility (48% at both rounds), 
injecting in the comfort of their own home (45% at 3 months and 53% at 6 months), injecting on their own time 
(44% at 3 months and 45% at 6 months), and not having to wait at the facility (40% at 3 months and 47% at 6 
months).  
 
FIGURE 13. REPORTED BENEFITS OF HOME SELF-INJECTION AMONG CLIENTS WHO 
SELF-INJECTED AT HOME AT 3 MONTHS OR 6 MONTHS 
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Self-injection clients were trained on how to properly store the DMPA-SC doses and dispose of the used 
Uniject™ devices, and were asked at 3 months and 6 months how they stored and disposed of the devices 
(Figure 14). Ninety-one percent of home self-injection clients reported correctly storing the doses in a cool, dry 
area at room temperature, and this increased to 96 percent at 6 months. Nearly all home self-injection clients 
reported correctly disposing of the used Uniject™ in a coverable and puncture-proof container (99% at 3 
months and 98% at 6 months). At 3 months, 24 percent of home self-injection clients reported returning the 
puncture-proof container to the health facility and this proportion rose to 37 percent at 6 months. Because 
respondents would have had only two used devices to dispose of during the study period and a re-supply would 
only have been necessary at 9 months, returning the container4 to the health facility was not necessary by 6 
months.  
 
FIGURE 14 .  CLIENTS’  METHODS FOR STORAGE AND DISPOSAL OF THE DMPA-SC 
UNIJECT™  
  
  
                                                     
4 The container used in this study could hold up to 5 used Uniject™ devices comfortably (see Appendix 3 for example of 
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Figure 15 presents clients’ reported ease of storage and disposal of DMPA-SC. Almost all of home self-injection 
clients found it easy to store the DMPA-SC doses (95% at 3 months and 94% at 6 months), and at each interview, 
96 percent found it easy to dispose of the used device. 
 
FIGURE 15. EASE OF STORAGE AND DISPOSAL OF DMPA-SC 
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Clients who chose home self-injection were trained on how to calculate future reinjection dates and were given 
a reinjection calendar to aid their calculation. Figure 16 illustrates clients’ reported reinjection time at 6 months, 
among those who self-injected at home at both 3 months and 6 months. Reinjection time was calculated by 
counting the days between the reported date of a client’s most recent injection at 3 months and the reported 
date of a client’s most recent injection at 6 months. Those who reinjected within the 11-to-17-week reinjection 
window were considered to have reinjected on-time (PATH 2018), while those who did so before 11 weeks had 
elapsed were considered early and those who reinjected after more than 17 weeks were considered late. Eighty-
five percent of self-injectors reported reinjecting on time, while 13 percent reported reinjecting early and 3 
percent reported reinjecting late.  
 
FIGURE 16 .  CLIENTS’  REPORT OF  REINJECTION TIME AT 6 MONTHS AMONG THOSE 
WHO SELF-INJECTED AT HOME AT 3 MONTHS AND 6 MONTHS (N=159)  
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A total of 150 providers were trained across the two study regions. Table 6 presents their background 
characteristics. The majority of trained providers were under 35 years of age (74%), female (91%) and had 
completed nursing training college (85%). Although represented by different cadres, almost two-thirds of 
providers were community health nurses (CHNs). Eighty-eight percent of providers had at least one year of 
professional experience in their current role, while 81 percent had at least one year of experience providing FP 
services. A slightly higher proportion of providers were trained in Volta region (53%) compared to Ashanti 
region (47%). Most facilities had between 21 and 25 FP-related providers trained (a combination of on-site and 
outreach providers); however, Piase CHPS and Tsito Health Centre, two facilities with smaller client volumes, 
each had seven providers trained.  
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TABLE 6. PERCENT DISTRIBUTION OF PROVIDERS BY SOCIODEMOGRAPHIC 
CHARACTERISTICS (N=150) 
  N Percent 
Age group*   
   19-24 8 5.3 
   25-29 41 27.3 
   30-34 61 40.7 
   35-39 8 5.3 
   40-44 3 2.0 
   45+ 10 6.7 
Gender   
   Male 14 9.3 
   Female 136 90.7 
Education completed   
   Senior secondary/High school 5 3.3 
   Nursing training college 127 84.7 
   University (undergraduate) 6 4.0 
   Post graduate degree 4 2.7 
   Other professional certificate  4 2.7 
Professional cadre*   
   Enrolled Nurse 9 6.0 
   Community Health Nurse (CHN) 98 65.3 
   Community Health Officer (CHO) 9 6.0 
   Midwife 21 14.0 
   Other 10 6.7 
How long have you been working in this professional capacity?*   
   Less than 1 year 13 8.7 
   1-4 years 59 39.3 
   5-9 years 41 27.3 
   10-19 years 23 15.3 
   20 or more years 9 6.0 
How long have you been providing FP*   
   Less than 1 year 16 10.7 
   1-4 years 58 38.7 
   5-9 years 36 24.0 
   10 or more years 27 18.0 
Region   
   Ashanti 71 47.3 
   Volta 79 52.7 
Residence   
   Rural 59 39.3 
   Urban 91 60.7 
Facility   
   Maternal & Child Health Hospital 21 14.0 
   Abuakwa Health Centre 21 14.0 
   Piase CHPS 7 4.7 
   Fumso Health Centre 22 14.7 
   Council Hall Family Health Unit 24 16.0 
   Helekpe Health Centre 23 15.3 
   Tsito Health Centre 7 4.7 
   Juapong Health Centre 25 16.7 
Total  150 100.0 
*Percentages may not add to 100 percent due to missing values  
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Figure 17 shows changes in provider knowledge of DMPA-SC from the pre-training self-administered 
questionnaire to the post-training self-administered questionnaire. Significant increases were observed across 
four knowledge questions. Provider knowledge that: the Uniject™ is the type of injection system used for 
DMPA-SC increased from 34 percent to 98 percent (p-value <0.001), DMPA-SC is administered subcutaneously 
increased from 29 percent to 93 percent (p-value <0.001), DMPA-SC is administered every three months 
increased from 52 percent to 99 percent (p-value <0.001), and DMPA-SC is stored at room temperature 
increased from 55 percent to 100 percent (p-value <0.001).  
 
FIGURE 17. CHANGES IN PROVIDER KNOWLEDGE OF DMPA-SC FROM PRE-
TRAINING TO POST-TRAINING (N=150)  
 
† p-value <0.001  
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Providers were asked where on the body DMPA-SC can be administered. Figure 18 shows that when comparing 
pre- and post-training responses, more providers correctly identified the location of DMPA-SC administration 
after receiving the training. While significant increases in knowledge were observed for upper arm (27% to 57%), 
abdomen (30% to 97%), and upper thigh (45% to 98%) as possible injection sites, only a little more than half of 
respondents recalled the upper arm as one such site at post-training, likely because the upper arm was not 
emphasized during the training due to it being a difficult location for clients to self-inject. Overall, all providers 
knew of at least one location where DMPA-SC could be administered after receiving the training.  
 
FIGURE 18. CHANGES IN PROVIDER KNOWLEDGE OF WHERE DMPA-SC CAN BE 
ADMINISTERED FROM PRE-TRAINING TO POST-TRAINING (N=150)  
 
†p-value <0.001  
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Almost all providers reported that they were very well prepared to offer DMPA-SC services after the training 
(Figure 19). Ninety-four percent of providers felt very well prepared to counsel clients on DMPA-SC, 93 percent 
felt very well prepared to administer DMPA-SC and to train clients to self-inject, and 97 percent felt very well 
prepared to observe and supervise clients during self-injection.  
 
FIGURE 19. PROVIDER-REPORTED PREPAREDNESS TO OFFER DMPA-SC SERVICES 
AT POST-TRAINING (N=150)* 
 
*Percentages may not add to 100 percent due to missing values 
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This study assessed the feasibility and acceptability of the subcutaneously administered injectable contraceptive 
known as DMPA-SC, or by its brand name Sayana® Press. The study assessed feasibility and acceptability from 
the perspective of: (1) service providers in Ghana who received training on DMPA-SC administration and on 
how to train clients to self-inject and (2) Ghanaian FP clients who voluntarily selected the subcutaneous 
injectable after counseling. At each injection time over a 6-month period (covering 3 injections), DMPA-SC 
clients chose between provider-administered injection or self-injection on each of these occasions. Results of 
the study have been used to inform the scale-up of DMPA-SC, including self-injection, in Ghana’s public and 
private sectors.  
Approximately two out of five DMPA-SC clients in this study (41%) had never used any method of FP, while 
48 percent of clients had recently used intramuscular injectables (DMPA-IM). Many new users (70%) continued 
to use the method through the study duration, suggesting that DMPA-SC is a feasible and acceptable option for 
new users of FP. Adding DMPA-SC to the method mix in Ghana will provide an additional FP option and 
increase the range of methods offered, which will increase choice for method selection. Reaching both new and 
previous users of FP with this new method could lead to an increase in modern contraceptive use (Ross and 
Stover 2013), helping Ghana to meet its FP2020 goals.  
This study originally estimated that by 6 months, 25 percent of DMPA-SC users would choose to self-inject. 
While just over one-third of DMPA-SC clients chose to self-inject the first time they used DMPA-SC (35%), 
nearly two-thirds (65%) chose to self-inject at both 3 months and 6 months, suggesting that women may become 
more comfortable with self-injection after receiving their first injection from the provider. Self-injection was 
selected more often among 18 to 34-year-olds, never-married women, first-time FP users, and women living in 
rural areas.  
These data confirm that self-injection is acceptable to a variety of women and specifically has the potential to 
reach vulnerable and marginalized populations with contraceptive needs. For example, women who live in rural 
areas may live further away from facilities that offer FP and could benefit from an option that allows them to 
self-inject in the home and return to the facility less often (if at all). Younger and never-married women may 
value new discrete and private ways of using contraception through self-injection. Expanding the availability of 
DMPA-SC to the private sector in addition to the public sector may be an opportunity to reach additional 
women for whom pharmacies and medical sellers are the preferred source of FP due to locations, hours, and 
privacy, among other conveniences.  
This study followed women through three cycles of DMPA-SC injection. By 6 months, two out of three (67%) 
women were still using DMPA-SC, a total of 9 months of protection. Continuation was more common in select 
subgroups, such as never-married women, women from Volta region, and new FP users. Most women who 
discontinued (n=80) did so due to method-related reasons, including the experience of side effects (44%), though 
others found DMPA-SC inconvenient (23%) or switched to a different FP method (16%). The proportion of 
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discontinuation due to side effects found in the present study is similar to that of DMPA-IM, where, according 
to the latest Demographic and Health Survey in Ghana, 44 percent of episodes of DMPA-IM use were 
discontinued due to side effects (GSS 2015).  
These findings highlight DMPA-SC’s high acceptability and its potential to reduce known barriers to 
continuation of contraceptive use, especially for clients that may be harder to reach, including never-married 
women and new FP users. The findings also demonstrate the importance of supporting women who experience 
side effects to manage their side effects or those or want to discontinue for other reasons to switch to a different 
FP method as long as their desire to prevent pregnancy remains.  
At 3 months, nearly two-thirds (65%) of DMPA-SC clients chose self-injection, including 21 percent that 
returned to the facility to self-inject in the presence of a provider and 44 percent who self-injected at home. 
Furthermore, clients who took DMPA-SC doses home reported high satisfaction (98% at 6 months) and comfort 
(100% at 6 months) with home self-injection, and over 85 percent reported experiencing at least one benefit of 
home self-injection, such as not having to travel to the facility, not having to wait at the facility, increased visual 
privacy, and not having to be attended by the provider at the facility. These findings resonate with those of other 
self-injection studies (e.g., Burke et al. 2014; Cover et al. 2017a) and highlight self-injection of DMPA-SC as a 
self-care method that can increase women’s reproductive autonomy and decision making about timing, spacing, 
and limiting of childbearing (Murray et al. 2017). In addition to being acceptable to women, responses from 
interviews confirm that home self-injection is a feasible way to use DMPA-SC. For the majority of women who 
chose this mode of administration at 6 months, they knew how to correctly store (96%) and dispose of (98%) 
the used Uniject™ device, found it easy to store (94%) and dispose of (96 percent), and reinjected on time (i.e., 
11 to 17 weeks after last injection) (85%). However, 15 percent did not reinject on-time, with 13 percent injecting 
early and 2 percent injecting late. This suggests that additional training on calculating and remembering 
reinjection dates would be helpful for home self-injection clients. This may include text message reminders or 
pocket calendars so that women can identify the reinjection period for the year based on the date of the first 
injection.  
Training service providers to administer DMPA-SC as well as to train clients to self-inject was feasible, likely 
due in part to the fact that: (1) even the lowest cadre of GHS service providers, i.e., community health nurses, 
are already trained to offer intramuscular contraceptive injectables as well as subcutaneous vaccinations and (2) 
in-service/on-the-job training was conducted among all providers affiliated with FP at the facility. The training 
that providers participated in focused on the features of DMPA-SC and client self-injection practice through 
role plays, which were effective in significantly increasing provider knowledge of key DMPA-SC characteristics. 
After the training, at least 93 percent of providers could name the type of injection device used, how DMPA-
SC is administered, the frequency of DMPA-SC injections, and how to store DMPA-SC, compared to less than 
60 percent that could name each before the training. One hundred percent could name at least one location on 
the body where DMPA-SC could be administered after the training, compared to 61 percent before the training. 
These findings suggest that by using a standardized training curriculum, FP providers in Ghana can be trained 
in DMPA-SC and can train clients in DMPA-SC self-injection.  
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The training was effective in equipping providers with the tools to offer DMPA-SC services, as almost all 
providers reported feeling very well prepared to provide DMPA-SC services after the training. Providers 
reported feeling very well prepared to counsel women on DMPA-SC (94%), administer DMPA-SC to clients 
(93%), train clients on self-injection (93%), and observe and supervise clients who choose self-injection (97%). 
The hands-on training and supportive environment—role playing, injection practice, and opportunity to ask 
questions—may have increased the confidence of providers to provide DMPA-SC services. 
Providers did not systematically complete the self-injection practice observation checklist, citing that the steps 
to observe were easy to memorize. However, this limited study results on one of the indicators of client self-
injection competence. The national scale up implementation should consider whether the practice observation 
checklist would be a viable indicator of client competence during trainings.  
Another limitation of this study was the possible introduction of selectivity bias by excluding FP clients who 
were not unable to provide a phone number as a contact or unwilling to be reached by phone. The necessity of 
a phone contact was due not only to the longitudinal nature of the study, but also the high chance of clients in 
our sample opting for home self-injection. National data show that 90 percent or more of Ghanaian households 
own a mobile telephone (GSS et al. 2015; Laary 2016). Nevertheless, it is possible that the characteristics of FP 
clients who could not provide a phone number as a contact or were unwilling to be reached by phone would be 
different from FP who could and were willing.  
A third limitation of this study is that it did not include FP clients below 18 years old who sought services at the 
study sites. While gaining the perspectives of adolescents on the feasibility and acceptability of DMPA-SC and 
self-injection is important, the TAG decided to exclude this subgroup for two main, related reasons: first, to 
protect the privacy, anonymity, and confidentiality of the adolescents in the event that their FP use was unknown 
to their parents or guardians; and second, the short enrollment period could not allow time for data collectors 
to locate all parents or guardians and seek their consent prior to seeking assent from the adolescent.  
This study has several strengths:  
• This study responded to a direct need for evidence generation and added to the body of evidence on 
subcutaneous contraceptive injection in low-resource settings.  
• This study followed clients prospectively over 6 months, reducing their recall bias in reporting on 
experiences using DMPA-SC.  
• This study was deliberately designed for clients to decide voluntarily at each injection their preferred 
administration method, allowing those who chose a provider-administered injection at their first 
injection to still have the option to self-inject at 3 and/or 6 months and vice versa. As the proportion 
of clients choosing self-injection nearly doubled from 35 percent at the first injection to 65 percent at 3 
months and remained constant at 6 months, this study design showed that more clients may be willing 
to choose self-injection after experiencing the first injection with a provider.  
• By completing this study, Ghana became the first example in sub-Saharan Africa of introducing DMPA-
SC and self-injection simultaneously, and successfully doing so.  
• A multi-sectoral TAG was created intentionally to include private sector representatives that would 
provide input from the start and utilize research findings to inform strategy in the event of a national 
scale-up.  
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• Results from the research study have been used to inform the national scale up of DMPA-SC and self-
injection in public and private facilities, for which implementation planning by GHS began in January 
2019. Members of the TAG were called to participate in and contribute to the scale-up working group.  
The findings of this study suggest that providers can effectively counsel their clients on DMPA-SC, be trained 
to provide DMPA-SC, and train clients who voluntarily choose the self-injection mode of administration. The 
study findings also demonstrate that clients benefitted from the option to self-inject and the personalized training 
and supervision by the health provider. Training providers to offer DMPA-SC services and train clients to self-
inject could expand access to FP for new users and continuation of FP among current or previous FP users. 
Though home self-injection was feasible for most women, particular attention and support may be needed to 
ensure that home self-injection clients are able to reinject on time, safely store and dispose of DMPA-SC, and 
manage side effects, and that those who want to discontinue for method-related reasons are able to switch to a 
different FP method. 
As of 2017, GHS has over 21,000 enrolled nurses and over 15,000 community health nurses (GHS 2018), 
representing a substantial pool of lower cadre health personnel—more likely to be stationed in rural and peri-
urban areas and to conduct outreach/home visits. As shown by this study, these providers can readily be trained 
on DMPA-SC and client self-injection. The findings of this study support the national scale-up of DMPA-SC, 
and the following considerations are recommended to assist the GHS:  
: 
• Develop an implementation strategy for staggered rollout across the nation in public and private health 
facilities.  
• Utilize a cascade training approach similar to the study, whereby national and regional resource persons 
are trained to become Master Trainers, who then train providers on-site. This will efficiently maximize 
the number of providers who are trained across the country. 
• Engage pharmacies and over-the-counter medical sellers in commodity resupply, enabling them to sell 
DMPA-SC to women who have received self-injection training at the facility and amplifying the role of 
the private sector in increasing uptake of DMPA-SC in Ghana.  
: 
• Develop national guidelines and standards governing home self-injection of DMPA-SC, to be included 
in the next edition of the National Reproductive Health Service Policy and Standards. 
• Develop national guidelines and standards for disposal and waste management of used devices for 
facilities and home self-injection clients. 
: 
• Raise awareness by integrating DMPA-SC in relevant health promotion and social marketing activities 
in the community and at health facilities. 
: 
• Enforce the use of the standard Adverse Reaction Reporting Form in public and private facilities as well 
as pharmacies and over-the counter medical seller shops as part of pharmacovigilance. 
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• Add DMPA-SC and its modalities as a method option on FP registries and daily logs to enable public 
and private facilities to contribute to national monitoring and reporting of DMPA-SC use. 
• Include global DMPA-SC indicators in monitoring and evaluation tools to enable comparisons of trends 
with other countries.  
• Develop an action plan for monitoring disposal and waste management for facilities and home self-
injection clients. While 95 percent of clients stored DMPA-SC correctly and 98 percent disposed of it 
correctly, this study did not follow women for long enough to know if they would also return their 
disposal container to the facility at the time of resupply. 
• Conduct regular assessments of client experiences with DMPA-SC, including reinjection, storage, and 
disposal practices, as well as reasons for discontinuation of DMPA-SC, and a comparison of these 
reasons to those for discontinuation of DMPA-IM. As self-injection is a new mode of administration 
in Ghana, monitoring its use from the clients’ perspective will be critical in understanding successes and 
challenges of home injection for learning across the region.  
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APPENDIX 1. STUDY PARTNERS AND ROLES 
Partner Roles 
GHS Provide access to family planning users at public health facilities  
USAID Stakeholder and study funder 
UNFPA Supply DMPA-SC commodities (expected 6,000 doses) 
Population Council via 
Evidence Project  
Lead research study; coordinate implementation, data analysis, and research 
utilization 
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APPENDIX 2 .  CLIENT’S MODE OF INJECTION ADMINISTRATION AT ALL INTERVIEWS, BY SOCIODEMOGRAPHIC 
CHARACTERISTICS 
  First injection 3 months  6 months 
  
Provider-
administered 
On-site 
self-
injection 
Total 
(n) 
Provider-
administered 
On-site self-
injection 
Home self-
injection 
Total 
(n) 
Provider-
administered 
On-site self-
injection 
Home self-
injection 
Total 
(n) 
Age group            
   18-24 63.2 36.8 185 28.4 26.2 45.4 141 22.3 32.1 45.5 112 
   25-29 61.5 38.5 156 29.4 12.8 57.8 109 26.0 17.7 56.3 96 
   30-34 67.3 32.7 107 30.1 23.7 46.2 93 22.1 27.9 50.0 86 
   35-39 66.1 33.9 62 34.0 27.7 38.3 47 35.6 28.9 35.6 45 
   40+ 73.7 26.3 57 39.5 25.6 34.9 43 48.7 15.4 35.9 39 
            
Marital status    
   
 
   
 
   Never married 62.6 37.4 155 25.4 23.8 50.8 122 19.5 25.7 54.9 113 
   Ever married/in-union 65.9 34.1 413 32.8 21.9 45.3 311 30.9 25.3 43.8 265 
            
Education    
   
 
   
 
   No education 74.6 25.5 55 40.0 28.6 31.4 35 35.5 29.0 35.5 31 
   Primary 70.1 29.9 107 24.1 39.8 36.1 83 21.4 38.6 40.0 70 
   JSS/JHS 65.6 34.4 282 33.0 17.7 49.3 221 30.7 21.7 47.6 189 
   SSS/SHS or higher 54.8 45.2 124 27.7 16.0 56.4 94 22.7 21.6 55.7 88 
            
Region    
   
 
   0.00 
   Ashanti 73.7 26.3 278 50.6 14.1 35.3 170 47.5 15.6 36.9 160 
   Volta 56.6 43.5 290 17.9 27.8 54.4 263 12.8 32.6 54.6 218 
            
Residence    
   
 
  
 
 
   Rural 47.8 52.2 226 15.1 4.5 80.5 179 13.2 6.9 79.9 144 
   Urban 76.3 23.7 342 41.7 35.0 23.2 254 36.3 36.8 26.9 234 
            
Use of family planning    
   
 
   
 
   First-time FP users 60.7 39.3 234 24.1 24.6 51.3 191 18.7 28.3 53.0 166 
   All previous FP users 68.0 32.0 334 36.0 20.7 43.4 242 34.4 23.1 42.5 212 
Total  369 199 568 133 97 203 433 104 96 178 378 
Percent 65.0 35.0 100.0 30.7 22.4 46.9 100.0 27.5 25.4 47.1 100.0 
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APPENDIX 3. VISUALS OF DISPOSABLE PUNCTURE-PROOF CONTAINER, AND USED 
AND UNUSED UNIJECT  T M  DEVICES  
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